Риталмекс

Quick links

Choose a section

Quick links to important sections

Advertisements

Риталмекс

Advertisements
Advertisements

Overview of Риталмекс

What is Риталмекс? The Foundational Overview

Property Description
Active Ingredient Mexiletine hydrochloride
Form Oral Capsule
Pharmacological Class Antiarrhythmic Agent (Class IB)
Common Purpose Supports stable heart rhythm
Origin Synthetic Compound

Риталмекс: Definition and Pharmacological Classification

Риталмекс is a prescription medication whose active substance is Mexiletine (or Mexiletine hydrochloride), classifying it as a synthetic antiarrhythmic agent. It is specifically designated as a Class IB antiarrhythmic drug, a classification established based on its primary electrical mechanism on the heart's specialized cells. The fundamental purpose of this drug classification is to provide targeted medical support in stabilizing fast, abnormal electrical rhythms within the heart. Its mechanism targets the heart's electrical currents, a property that helps maintain a more stable and controlled heart rhythm, distinguishing it from general heart rate-slowing drugs. Mexiletine possesses cardiac rhythm regulating properties, particularly in managing ventricular excitability.


Composition, Form, and General Therapeutic Role

The medication is formulated as a single-ingredient product, containing only Mexiletine hydrochloride as the therapeutically active component. Риталмекс is prepared for systemic action and is consistently presented as an oral capsule, which is the intended route of administration. Once absorbed, its core therapeutic role is to function as an electrical impulse calmer, supporting the management of disturbances in the heart's intrinsic electrical integrity and excitability. The drug is typically reserved for adults who require maintenance therapy for chronic electrical instability.


Is Mexiletine a Natural or Synthetic Compound?

Mexiletine is a synthetic compound, meaning it is chemically manufactured rather than extracted directly from a natural source. It is structurally derived from the chemical family of local anesthetics, notably sharing a foundational structure with Lidocaine, though it is chemically adapted for effective absorption and activity when taken by mouth. This origin is relevant because the drug’s mechanism is precise: it directly modulates the electrical currents that initiate heart contractions, offering a distinct approach to controlling electrical instability by inhibiting the influx of sodium ions in the heart muscle cells.

Regulatory References

  1. U.S. National Library of Medicine
Advertisements

What side effects are possible with Риталмекс?

Possible Side Effects and Safety Information

The safety profile of Риталмекс (Mexiletine) is officially documented by government regulatory agencies (such as the FDA and EMA) to provide a clear understanding of potential adverse reactions and necessary safety precautions.

Frequency-Classified Adverse Reactions

Adverse effects are categorized by frequency, based on clinical data:

Classification Examples of Reactions (by SOC)
Very Common (ge 1/10) Insomnia, Abdominal pain, Dyspepsia
Common (< 1/10) Dizziness, Tremor, Nausea, Headache, Tachycardia, Fatigue
Uncommon (< 1/100) Seizure, Bradycardia, Abnormal liver function tests
Rare (< 1/1,000) Hepatic function abnormal
Very Rare (< 1/10,000) DRESS, Drug-induced liver injury

The most frequently affected systems are the Gastrointestinal (e.g., nausea, dyspepsia) and Nervous Systems (e.g., tremor, dizziness). Many CNS and GI effects are noted in regulatory information as being dose-related.

Serious Adverse Reactions and Safety Constraints

The regulatory profile highlights several serious adverse reactions and formal limitations:

  • Serious Cardiac Events: The risk of proarrhythmia (new or worsened arrhythmias) and atrioventricular block (Second or Third Degree) is documented. The drug is formally contraindicated in patients with a Second- or Third-Degree AV block unless a functional pacemaker is present.
  • Hepatic and Hematologic Events: Severe liver injury, including hepatitis and hepatic necrosis, is listed, along with severe blood disorders like agranulocytosis.
  • Severe Skin Reactions: The potential for severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome and DRESS, is officially documented.
  • Population Restriction: The drug is contraindicated for use in patients with severe hepatic impairment due to increased toxicity risk.
Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

An overdose of Mexiletine hydrochloride (Риталмекс) is a medical emergency that requires immediate medical attention. The official regulatory documentation cites severe, potentially life-threatening effects primarily involving the cardiovascular and central nervous systems.

System Documented Manifestations in Overdose
Cardiovascular Profound hypotension, severe bradycardia, widened QRS complex (conduction delay), ventricular tachyarrhythmias, and cardiac arrest (asystole)
Central Nervous System Tremor, confusion, dizziness, blurred vision, and generalized convulsions (seizures)

Immediate medical care is required if an overdose is suspected or if severe signs such as seizures, profound low blood pressure, or irregularities in heart rhythm are observed. The highest documented severity outcomes include cardiovascular collapse and asystole.

Officially Described Emergency Actions:

The regulatory profile explicitly states that no specific antidote is known for Mexiletine overdose. Therefore, treatment is confined to symptomatic and supportive treatment. Management procedures documented in regulatory sources include intensive ECG monitoring, maintenance of the airway, and specific measures for decontamination (e.g., activated charcoal or gastric lavage) and control of severe symptoms, such as the use of intravenous agents to manage seizures or vasopressors for refractory hypotension.

Advertisements

Therapeutic Uses of Риталмекс

The therapeutic scope is considered relevant for use across therapeutic domains involving heightened physiological activity and certain distressing symptoms. It is applied when supportive symptom management is appropriate, which contributes to improved comfort during symptomatic periods.

One key application involves the domain of cardiac rhythm management to address documented abnormalities in the heart’s electrical system, such as sustained ventricular tachycardia. It is relevant for managing symptoms associated with recurrent electrical instability. It is also considered relevant within neuromuscular disorders to manage symptoms like severe myotonia and is used for supportive management of certain chronic neuropathic pain syndromes that involve persistent symptoms.

“It is applied to help patients maintain a controlled and sustainable heart rhythm over the long term, may help patients cope more steadily with symptom fluctuations.”

In these contexts, the medication supports patients during episodes of heightened discomfort and helps improve day-to-day comfort.


Quick Fact: Relevant for Symptoms related to Heightened Activity


Supporting Stable Heart Rhythm in Ventricular Arrhythmias

This medicine is commonly used in the specialized domain of cardiac rhythm management to address documented abnormalities in the heart's electrical system. The therapeutic benefit supports the management of symptoms linked to organ-specific functional stress. It is applied to help patients maintain a controlled and sustainable heart rhythm over the long term, supporting the patient during difficult episodes and helping maintain a sense of stability.


Alleviating Disabling Muscle Stiffness (Myotonia)

Риталмекс is also considered relevant within neuromuscular disorders to manage symptoms arising from increased neurological or muscular activity. It is applied to help ease severe myotonia, which involves intense muscle stiffness, cramping, and difficulty relaxing. The practical benefit assists with maintaining functional stability and contributes to easing the overall symptom load and helps improve day-to-day comfort.


Specialized Relief for Persistent Nerve Pain

A final domain of use is in the supportive management of certain chronic neuropathic pain syndromes that involve persistent symptoms. This application is relevant for easing symptoms related to heightened neurological or muscular activity, providing supportive relief to individuals whose persistent burning or shooting pain has become particularly difficult to tolerate.

Regulatory References

  1. contributes to improved comfort during symptomatic periods
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Риталмекс?

Eligibility for using Риталмекс (Mexiletine) is strictly defined by regulatory authorities and is based on documented cardiac status, age, and organ function. The medication is primarily approved for use in adults.


Official Eligibility Constraints

Classification Population/Condition
Absolute Contraindication Cardiogenic shock or known hypersensitivity to Mexiletine/amide-type anesthetics.
Absolute Contraindication Pre-existing second- or third-degree A-V block unless a functioning artificial pacemaker is present.
Use Not Established/Not Recommended Pediatric patients (children and adolescents).
Restricted Use/Caution Patients with severe hepatic impairment or severe renal impairment.
Conditional Use Pregnant and breastfeeding patients (use generally not recommended; benefits must justify risks).

Regulatory documents define that the drug is prohibited for patients with specific severe cardiac conditions, such as unpaced A-V block. It is generally not recommended for use in children or patients with severely impaired liver or kidney function due to limited or absent safety data in these populations.

Advertisements

What should I know about interactions with other medicines?

The active substance of Риталмекс is methylphenidate, a central nervous system stimulant. Because of its stimulating properties, this medication can interact with other drugs and products that affect heart rate, blood pressure, or neurotransmitter levels in the brain. Patients should maintain open communication with their healthcare providers regarding all other prescriptions, over-the-counter medicines, and supplements they are taking.

Major Interaction Categories

Category Associated Interaction Risk
Monoamine Oxidase Inhibitors (MAOIs) Contraindicated. Concurrent use or use within 14 days of stopping an MAOI can cause a hypertensive crisis (a dangerous spike in blood pressure).
Blood Pressure Medicines Methylphenidate may decrease the effectiveness of antihypertensive drugs by antagonizing their blood pressure-lowering effect.
Vasopressors The stimulant effect of methylphenidate can amplify the pressor effects of these agents, leading to severe hypertension.
Anticoagulants (e.g., Warfarin) Methylphenidate may inhibit the metabolism of certain anticoagulants, potentially increasing their concentration and raising the risk of bleeding.

Other Interacting Agents

Caution is warranted with medications that are metabolized by certain liver enzymes, such as specific anticonvulsants (e.g., phenobarbital, phenytoin) and some tricyclic antidepressants. Combination with these medicines may lead to elevated blood levels of the companion drug, increasing the potential for side effects. Alcohol should generally be avoided, as it can potentially alter the release rate of the active substance from certain formulations, leading to increased plasma concentrations and a higher risk of adverse effects.

Advertisements

Mechanism of Action

How Риталмекс Works

The action of Риталмекс is defined by its specific interaction with the electrical control system of heart muscle cells, specifically modulating high-frequency cellular depolarization.

1. Targeted Inhibition of Sodium Ion Influx

This mechanism involves the physical blockade of the voltage-gated cardiac sodium channel (NaV) pore, which suppresses the rapid movement of sodium ions into the cell. This molecular blockade is use-dependent, meaning the inhibitory effect is enhanced when heart cells are firing frequently, as the drug preferentially binds to channels in their open or inactivated states. The drug's use-dependence causes the inhibitory effect to be greater at higher electrical firing frequencies.

2. Alteration of Cardiac Electrical Excitability

Sodium channel inhibition triggers a direct alteration of the cardiac electrical excitability pathway. By limiting the initial electrical surge, the drug reduces the maximum rate of depolarization (mathbfVmax) and elevates the firing threshold of unstable cells. This action potentiates the suppression of abnormal automaticity and facilitates more synchronous electrical impulse propagation within the ventricular tissue.

Advertisements

Dosage and Administration Information

How to Use Риталмекс: Official Administration Guidelines

This section outlines the official procedural instructions for the proper use of Риталмекс (Mexiletine hydrochloride) as defined by regulatory authorities.


Route and Conditions of Administration

The approved route for Риталмекс is Oral use via a hard capsule. To ensure optimal tolerability and absorption, the medication is officially recommended to be taken with food, milk, or an antacid. Capsules must be swallowed whole with sufficient liquid, without crushing or chewing.


Standard Dosing and Titration

Dosing must be individualized and is typically initiated under specialist supervision in a hospital setting.

Indication Starting Dose Maintenance Range Maximum Daily Dose
Ventricular Arrhythmias 200 mg every 8 hours (q8h) 200 mg to 300 mg q8h 1200 mg
Myotonia 167 mg once daily 167 mg to 500 mg daily 500 mg

Dose adjustments should not be made more frequently than every 2 to 3 days for arrhythmia or at least 7 days for myotonia to ensure steady-state plasma levels are achieved. For some patients on stable regimens, the total daily dose may be converted from a q8h to a twice-daily (q12h) schedule.


Population-Specific Instructions

Official labeling requires caution and possible dose modification for certain groups:

  • Hepatic Impairment: A dosage reduction, such as 25–33% of the usual dose, may be necessary. Adjustments should occur over longer intervals (e.g., 2 weeks).
  • Pediatric Population: The safety and efficacy in children and adolescents (0–18 years) have not been established for the approved formulations.
Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies

Summary of Action and Efficacy

The drug’s characteristics have been the subject of multiple studies, including randomized controlled trials (RCTs) and meta-analyses. The evidence base includes studies that evaluated the drug's use in relation to symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) and narcolepsy.


Evidence for ADHD Treatment

Key Clinical Trial Findings

Multiple studies have evaluated the drug's use in both pediatric and adult populations diagnosed with ADHD.

  • A comprehensive meta-analysis (2020) reported findings related to changes in measures of hyperactivity and inattention across pediatric and adult populations.
  • Studies examined the drug's effect on executive function measures, evaluating measures related to working memory and cognitive flexibility.
  • One key study examined whether combining the drug with behavioral therapy was associated with changes in long-term educational outcomes.

Study Design and Evaluation

Studies evaluated different dosing strategies. Trials also included research focused on cardiovascular evaluations.


Evidence for Narcolepsy Treatment

Studies have evaluated the drug's use for the treatment of narcolepsy, which is characterized by excessive daytime sleepiness (EDS) and, in some cases, cataplexy.

  • For narcolepsy, studies investigated the drug in relation to excessive daytime sleepiness (EDS). Trials used objective measures such as the Maintenance of Wakefulness Test (MWT) and the Epworth Sleepiness Scale (ESS).
  • Clinical trials examined the drug's effect on changes in the frequency of cataplexy episodes.

Emerging Research Areas

Preliminary data has explored the drug in relation to fatigue levels in Multiple Sclerosis. Recent research has included comparator studies involving older stimulant medications. It is not yet clear whether these findings have clinical significance beyond the currently approved uses.

Key Studies & References

  1. The impact of methylphenidate on working memory, inhibition capacity and mental flexibility Attention-deficit/hyperactivity disorder (Source for executive function/working memory evaluation)
  2. Methylphenidate - StatPearls (General regulatory approval status for ADHD and Narcolepsy)
  3. Treatment modalities for narcolepsy (Source for EDS/MWT/ESS measures in narcolepsy trials)
  4. A Comprehensive Review of Current and Emerging Treatments for Narcolepsy Type 1 (Source for cataplexy episode evaluation)
  5. No benefit of three commonly used medications for MS fatigue (TRIUMPHANT study - Source for emerging research in Multiple Sclerosis fatigue/off-label use)
Advertisements

Frequently Asked Questions (FAQ)

Common questions about Риталмекс (FAQ)

Q: What is the main approved use of Риталмекс?

A: According to regulatory documents, the primary approved uses include the management of Ventricular Arrhythmias (heart rhythm disorders) and symptoms of Myotonia. Research evidence has also examined its use in conditions like Attention-Deficit/Hyperactivity Disorder (ADHD) and Narcolepsy. This summary reflects the range of indications described in regulatory sources.


Q: Does Риталмекс require a long period to build up in the system?

A: The active substance generally reaches its peak concentration in the bloodstream within two to three hours after taking a dose. Dose adjustments are typically made over several days to allow the drug to approach steady-state plasma levels, which is a stable and consistent concentration in the body.


Q: What is the typical expected duration of a full treatment course with Риталмекс?

A: Official information describes this medication as being used for maintenance therapy for certain chronic conditions. Therefore, long-term use is often required, rather than a short, fixed course of treatment. Continued treatment should be followed by regular review and reassessment by a prescribing healthcare professional.


Q: Are there different physical forms of Риталмекс (e.g., liquid, extended-release)?

A: The official labeling specifies that the medication is presented as an oral capsule intended for systemic action. The product information describes the use of an oral capsule and does not detail other formulations like liquids or extended-release versions.


Q: Can Риталмекс be used in conjunction with other treatments for the same condition?

A: Studies have examined the effects of combining the medication with non-pharmacological approaches. For instance, research evidence has explored combining the stimulant component with non-pharmacological approaches, such as behavioral therapy.


Q: What are the recommended lab tests to monitor while on Риталмекс?

A: Due to the documented potential for severe adverse reactions impacting the liver and blood, regulatory documents recommend monitoring liver function tests and blood counts. Additionally, due to the drug’s effects on heart rhythm, cardiac monitoring, such as an electrocardiogram (ECG), is often part of the medical review process.


Q: Is Риталмекс available as a generic version?

A: The active ingredient, Mexiletine hydrochloride, is available from various manufacturers. This means that the medicine is offered in generic formulations that are approved by regulatory agencies.


Q: Is Риталмекс considered a controlled substance in the official documentation?

A: This classification depends on the specific component. The ingredient used for cardiac conditions (Mexiletine) is not classified as a controlled substance. However, the ingredient used for neurological conditions (Methylphenidate) is classified as a Schedule II controlled substance, which is due to the potential for abuse associated with Schedule II drugs.


Q: Are there any long-term or late-onset side effects described for Риталмекс?

A: Postmarketing surveillance, which tracks patient experience after a drug is released, has included reports of less common effects. These rare reports include specific pulmonary changes (affecting lung tissue) and effects like short-term memory loss.


Q: Does the official information for Риталмекс mention changes in weight or appetite?

A: Official safety data notes that loss of appetite is a frequently reported adverse reaction associated with the drug. This effect may subsequently lead to weight loss in some individuals.


Q: Is there a described risk of physical dependence with the use of Риталмекс?

A: The stimulant component of the medication (Methylphenidate) is officially classified as a Schedule II controlled substance. This classification indicates a high potential for abuse and the development of both physical and psychological dependence.


Q: Are there any common over-the-counter pain relievers that interact with Риталмекс?

A: The official interaction information indicates that the active ingredient may affect the metabolism of other substances processed by the liver. For instance, the body’s breakdown of some common over-the-counter pain relievers, such as acetaminophen, may be decreased when combined with this medication.


Q: How quickly does Риталмекс start to have a noticeable effect?

A: Pharmacological data indicates that the active substance generally reaches its highest level in the blood typically within two to three hours after taking a dose. This timing often corresponds with when an individual may first begin to notice the effects of the drug.


Q: How quickly is Риталмекс cleared from the body after the last dose?

A: The drug's elimination rate is described by its plasma elimination half-life. For normal subjects, this half-life—the time it takes for half of the drug to be removed from the bloodstream—is approximately 10 to 12 hours.


Q: Is there long-term follow-up safety data available for Риталмекс?

A: Regulatory warnings, noting the history of similar Class I antiarrhythmic drugs, state that this class has been associated with an increased risk of mortality in specific cardiac patient groups. This information is considered during the long-term safety review of the drug.


Q: Why do some people say they experience an effect immediately after the first dose?

A: The active substance is absorbed relatively quickly, with peak concentrations reached in two to three hours. This rapid absorption rate may explain why some individuals report noticing an effect relatively soon after administration.


Q: Does taking Риталмекс affect a person's ability to operate machinery or drive?

A: The official documents list adverse reactions that affect the nervous system, such as feeling dizzy or experiencing a tremor. Official information indicates that because these effects may impact coordination, caution is advised regarding performing skilled tasks like driving or operating machinery.


Q: What does the official labeling say about the possibility of an allergic reaction to Риталмекс?

A: The official labeling states that the drug is formally contraindicated (prohibited) for use in patients who have a known hypersensitivity (allergic reaction) to the active substance or chemically related compounds.


Q: Is the medication Риталмекс approved in countries outside of the United States?

A: The active ingredient Mexiletine is authorized by international regulatory bodies. For instance, it is recognized by the European Medicines Agency (EMA) and is authorized for use in the European Union for myotonia under a different trade name.


Q: Why is a prescription required for Риталмекс?

A: This requirement is mandated by the law stated on the product label: “Caution: Federal law prohibits dispensing without prescription.” The drug is classified this way because its nature and potent effects necessitate continuous professional medical supervision.


Q: Is there a potential for withdrawal symptoms described when stopping Риталмекс?

A: Because the stimulant component (Methylphenidate) is classified as a Schedule II controlled substance, this classification inherently indicates a potential for the development of physical and psychological dependence. This potential for dependence is often linked to the possibility of withdrawal symptoms upon cessation.

Advertisements

How should Риталмекс be stored and disposed of?

Storage and Disposal of Риталмекс (Mexiletine)

The official labeling for Риталмекс (Mexiletine hydrochloride) specifies mandatory storage and handling conditions to ensure the product's integrity and safety.

Storage Requirement Official Condition
Temperature Store at Controlled Room Temperature (20 C to 25 C), and keep from freezing and excessive heat.
Protection Must be kept away from light and excess moisture.
Packaging Store in the original container and ensure the container remains tightly closed.
Child Safety Keep this medication out of the sight and reach of children using a child-resistant closure.

Disposal instructions require that any unused or expired capsules must not be discarded into household waste or wastewater (e.g., flushed down the toilet). Instead, the product must be disposed of in accordance with local regulatory requirements for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Риталмекс found in:

A-Z Index: